Jubilant Pharmova Limited is a global pharmaceutical and life sciences company, with a focus on pharmaceuticals, contract research, and proprietary novel drugs. Through its subsidiary Jubilant Pharma Limited, the company manufactures and supplies APIs, solid dosage formulations, radiopharmaceuticals, and more, operating six US FDA-approved facilities in India, the USA, and Canada. The company provides drug discovery and development services, and its proprietary novel drugs segment targets oncology and autoimmune diseases. Jubilant has a significant global presence with 48 radiopharmacies in the USA and recently expanded its chemistry research capacity in Greater Noida, India.
Founded in 1978, Jubilant Pharmova has evolved through strategic acquisitions and expansions, including a significant demerger of its Life Science Ingredients business in 2021. The company has 35 subsidiaries and a broad portfolio of drug filings across major markets. Recent developments include the expansion of injectable production capacity in Spokane, USA, and the launch of the I131-MIBG program for neuroblastoma treatment. The company continues to focus on innovation and strategic partnerships to enhance its pharmaceutical offerings globally.
